Related Experiment Video

Updated: Oct 1, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

Meningococcal vaccine against serogroups A, C, Y and W-135: new preparation. Encouraging immunogenicity studies

    Prescrire International
    |May 4, 2002
    PubMed

    Insights

    The four-valent meningococcal vaccine (A, C, Y, W-135) offers short-term protection against specific serogroups, but is less effective in young children. It is recommended for pilgrims and contacts when no better options exist.

    Area of Science:

    • Public Health
    • Vaccinology
    • Infectious Disease Epidemiology

    Background:

    • Meningococcal meningitis prevention relies on vaccination and chemoprophylaxis.
    • Key pathogenic serogroups include A, B, C, Y, and W-135, with variable geographic distribution.
    • Serogroup B is prevalent in France but lacks a vaccine; existing vaccines target A and C.

    Purpose of the Study:

    • To evaluate a meningococcal polysaccharide vaccine against serogroups A, C, Y, and W-135.
    • To assess its immunogenicity and efficacy, particularly for specific populations and serogroups.

    Main Methods:

    • Review of available data on a four-valent (A, C, Y, W-135) meningococcal polysaccharide vaccine.
    • Analysis of antibody response in adults and children under two years old.
    • Evaluation of reported protection against specific serogroups and duration of immunity.

    Main Results:

    • The vaccine elicits short-term antibodies in most adults against serogroups A, C, Y, and W-135.
    • It demonstrates poor immunogenicity in children under two, especially for serogroup C.
    • Efficacy against Y and W-135 is unknown; limited data exist for A and C. Protection wanes after two years, with ~95% efficacy against A and 65% against C at one year.

    Conclusions:

    • The four-valent vaccine shows acceptable safety profiles.
    • It is considered a better option than the two-valent (A+C) vaccine for pilgrims and contacts when facing serogroups A, C, Y, or W-135.
    • Limitations include poor immunogenicity in young children and unknown long-term efficacy for certain serogroups.

    More Related Videos

    Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

    Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

    Published on: May 19, 2020

    Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice08:52

    Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

    Published on: February 22, 2019

    Related Concept Videos

    Bacterial Meningitis01:24

    Bacterial Meningitis

    Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
    Bacterial Meningitis II: Pathophysiology01:26

    Bacterial Meningitis II: Pathophysiology

    Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
    Bacterial Meningitis I: Introduction01:22

    Bacterial Meningitis I: Introduction

    Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
    Streptococcal Pharyngitis01:27

    Streptococcal Pharyngitis

    Streptococcal pharyngitis, commonly known as “strep throat,” is an acute infection of the oropharyngeal tissues caused by the Gram‑positive Group A Streptococcus (Streptococcus pyogenes). Transmission occurs primarily through respiratory droplets expelled during coughing, sneezing, or talking.Mechanisms of Host Entry and Immune EvasionUpon entering the host, S. pyogenes adheres to the mucosal epithelial cells of the pharynx via surface proteins, notably lipoteichoic acid and the antiphagocytic...
    Viral Meningitis01:18

    Viral Meningitis

    Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
    Vaccine Production01:23

    Vaccine Production

    Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...